Sean Thomas Flynn
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sean Thomas Flynn.
Bioorganic & Medicinal Chemistry Letters | 2000
Helen F. Boyd; Stephen Christopher Martin Fell; Sean Thomas Flynn; Deirdre M.B. Hickey; Robert John Ife; Colin Andrew Leach; Colin H. Macphee; Kevin J. Milliner; Kitty Moores; Ivan Leo Pinto; Rod A. Porter; D. Anthony Rawlings; Stephen A. Smith; Ian Stansfield; David G. Tew; Colin J. Theobald; Caroline M. Whittaker
From two related series of 2-(alkylthio)-pyrimidones, a novel series of 1-((amidolinked)-alkyl)-pyrimidones has been designed as nanomolar inhibitors of human lipoprotein-associated phospholipase A2. These compounds show greatly enhanced activity in isolated plasma. Selected derivatives such as compounds 51 and 52 are orally active with a good duration of action.
Bioorganic & Medicinal Chemistry Letters | 2009
Paul W. Smith; Paul Adrian Wyman; Peter J. Lovell; Caroline J. Goodacre; Halina T Serafinowska; Antonio Vong; Frank P. Harrington; Sean Thomas Flynn; Daniel Marcus Bradley; Rod A. Porter; Sara A. Coggon; Graham Murkitt; Kirsten L. Searle; David R. Thomas; Jeannette M. Watson; William H. Martin; Zining Wu; Lee A. Dawson
Lead optimisation starting from the previously reported selective quinoline NK(3) receptor antagonists talnetant 2 (SB-223412) and 3 (SB-222200) led to the identification of 3-aminoquinoline NK(3) antagonist 10 (GSK172981) with excellent CNS penetration. Investigation of a structurally related series of sulfonamides with reduced lipophilicity led to the discovery of 20 (GSK256471). Both 10 and 20 are high affinity, potent NK(3) receptor antagonists which despite having different degrees of CNS penetration produced excellent NK(3) receptor occupancy in an ex vivo binding study in gerbil cortex.
Bioorganic & Medicinal Chemistry Letters | 2000
Helen F. Boyd; Sean Thomas Flynn; Deirdre M.B. Hickey; Robert John Ife; Martin Francis Jones; Colin Andrew Leach; Colin H. Macphee; Kevin J. Milliner; D. Anthony Rawlings; Brian Peter Slingsby; Stephen A. Smith; Ian Stansfield; David G. Tew; Colin J. Theobald
Starting from two weakly active hits from high throughput screening, a novel series of 2-(alkylthio)-pyrimidin-4-ones with high potency and selectivity for lipoprotein-associated phospholipase A2 has been designed. In contrast to previously known inhibitors, these have been shown to act by a non-covalent and substrate competitive mechanism.
Bioorganic & Medicinal Chemistry Letters | 2010
Dale James Johnson; Ian Thomson Forbes; Steve P. Watson; Vincenzo Garzya; Graeme I. Stevenson; Graham Walker; Harminder S. Mudhar; Sean Thomas Flynn; Paul Adrian Wyman; Paul W. Smith; Graham Murkitt; Adam Lucas; Claudette Mookherjee; Jeannette M. Watson; Jane Gartlon; Andrea Bradford; Fiona Brown
A series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles are reported which were found to be potent and selective muscarinic M1 agonists. By control of the physicochemical characteristics of the series, particularly the lipophilicity, compounds with good metabolic stability and excellent brain penetration were identified. An exemplar of the series was shown to be pro-cognitive in the novel object recognition rat model of temporal induced memory deficit.
Archive | 1990
William John Coates; Sean Thomas Flynn
Archive | 1998
Laramie Mary Gaster; Paul Adrian Wyman; Sean Thomas Flynn
Bioorganic & Medicinal Chemistry Letters | 2007
Simon E. Ward; Peter Eddershaw; Sean Thomas Flynn; Laurie J. Gordon; Peter J. Lovell; Susan H. Moore; Claire M. Scott; Paul W. Smith; Kevin M. Thewlis; Paul Adrian Wyman
Archive | 2003
Sean Thomas Flynn; Paul W. Smith; Kevin M. Thewlis; Simon E. Ward; Paul Adrian Glaxosmithkline Wyman
Bioorganic & Medicinal Chemistry Letters | 2005
Paul Adrian Wyman; Howard R. Marshall; Sean Thomas Flynn; Ron J. King; Mervyn Thompson; Paul W. Smith; Michael S. Hadley; Gary W. Price; Claire M. Scott; Lee A. Dawson
Archive | 1989
Wiliam John Coates; Sean Thomas Flynn; Derek Anthony Rawlings